Search Results
Your search for ,had matches 18600 pages
Showing 6501 - 6550ESMO Immuno-Oncology 2020: Tebentafusp Shows Activity in Metastatic Uveal Melanoma
Tebentafusp is a novel bispecific molecule consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100-positive cells. The agent showed clinical benefit, including target lesion reduction, in patients with metastatic uveal melanoma,...
Addition of Chemotherapy to Local Therapy in Women Aged 70 or Older With Triple-Negative Breast Cancer
In a National Cancer Database analysis reported in The Lancet Oncology, Crozier et al found that receipt of neoadjuvant or adjuvant chemotherapy was associated with improved overall survival among women aged 70 or older undergoing surgery for stage I to III triple-negative breast cancer. Study...
Changes in Care and Well-Being Among Patients With Cancer During Initial Stage of the COVID-19 Pandemic
In a Dutch study reported in JAMA Oncology, van de Poll-Franse et al found that a substantial proportion of patients with cancer had changes in care within 4 to 6 weeks after the first announcement of a COVID-19–related lockdown. Patients with cancer surveyed reported levels of quality of life,...
Spectrum of Germline-Somatic Interactions in Advanced Urothelial Cancer
In a study reported in Nature Communications, Vosoughi et al identified common germline-somatic variant interactions in advanced urothelial cancer, with these interactions appearing to play a central role in disease progression. As stated by the investigators, “The prevalence and the biologic...
Oral Panobinostat and Dexamethasone Plus Subcutaneous Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma
The randomized phase II PANORAMA 3 trial found that when used in combination with subcutaneous bortezomib and oral dexamethasone, oral panobinostat produced higher response rates with 20-mg dosing regimens and lower toxicity with a 10-mg regimen. The safety profile also appeared to be better than...
Postoperative Cancer Surgery Mortality Rates Have Improved, but Gap Still Exists Between Black and White Patients
Mortality rates after cancer surgery declined for Black as well as White patients during a recent 10-year period, although the mortality gap between the two groups did not narrow, according to new research published by Miranda Lam, MD, MBA, and colleagues in JAMA Network Open. The findings present...
ASH 2020: ctDNA May Indicate Increased Risk of Relapse After Stem Cell Transplant in Patients With DLBCL
Many patients with diffuse large B-cell lymphoma (DLBCL) may be cured by autologous stem cell transplant, but as many as half eventually relapse. New research presented by Reid Merryman, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition suggests...
ESMO Immuno-Oncology 2020: Does Pleural Effusion Affect Survival in Patients Treated With Immunotherapy for NSCLC?
Patients with non–small cell lung cancer (NSCLC) who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immune checkpoint inhibitors, according to findings presented by Epaillard et al at the European Society for Medical Oncology...
Pembrolizumab vs Chemotherapy in First-Line Treatment of Microsatellite Instability–High Advanced Colorectal Cancer: KEYNOTE-177 Trial
As reported in The New England Journal of Medicine, the second interim analysis of the phase III KEYNOTE-177 trial has shown significantly prolonged progression-free survival with pembrolizumab vs fluorouracil (5-FU)-based chemotherapy as first-line treatment of patients with advanced...
Cost-Effectiveness of Neoadjuvant/Adjuvant Treatment Strategies for HER2-Positive Breast Cancer
In a study reported in JAMA Network Open, Kunst et al compared five neoadjuvant-adjuvant treatment strategies for patients with HER2-positive breast cancer and identified one that was associated with both improved outcomes and cost savings. The researchers found that a strategy of neoadjuvant...
SABCS 2020: CTC Enumeration May Be Predictive of Survival During Treatment for Metastatic Breast Cancer
The number of circulating tumor cells (CTCs) assessed at baseline and about 1 month after cancer-directed treatment was associated with overall survival in patients with metastatic breast cancer, according to findings from a large retrospective pooled analysis reported by Wolfgang Janni, MD, PhD,...
SABCS 2020: RxPONDER Study Shows Postmenopausal Patients With Node-Positive Breast Cancer May Be Able to Avoid Chemotherapy
Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage, hormone receptor (HR)-positive, node-positive breast cancer. Based on the findings, many postmenopausal women may be able to safely skip adjuvant chemotherapy. However,...
ASH 2020: Phase II ZUMA-12 Study Investigates Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma
The phase II ZUMA-12 trial found that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is a safe and effective therapy for patients with high-risk large B-cell lymphoma. These results were presented by Sattva S. Neelapu, MD, and colleagues at the 2020 ...
SABCS 2020: Follow-up Data From monarchE Show Continued Abemaciclib Benefit in High-Risk, HR-Positive, HER2-Negative Breast Cancer
Extended follow-up results from the phase III monarchE trial showed that adding the cyclin-dependent kinase inhibitor abemaciclib to standard adjuvant endocrine therapy continued to improve invasive disease–free survival in patients with high-risk, node-positive, early-stage, hormone receptor...
SABCS 2020: Can Mindfulness Meditation and Survivorship Education Help to Reduce Depression in Young Breast Cancer Survivors?
New research showed that behavioral interventions—mindfulness meditation and survivorship education classes—may be effective in reducing depressive symptoms in younger breast cancer survivors. This patient population often experiences the highest levels of depression, stress, and fatigue, which may ...
Potential Impact of State Government Crisis Standards-of-Care Guidelines on Resource Allocation for Patients With Cancer
In a study reported in JAMA Oncology, Hantel et al found that among U.S. states with crisis standards-of-care guidelines, 55% deprioritized some patients with cancer in resource allocation and 26% included cancer-related categorical exclusions. As stated by the investigators, “State crisis...
Career Development Award Winner Dr. Aparna Parikh on the Emerging Importance of Liquid Biopsies for GI Cancers
Systematic liquid biopsies are transforming treatment approaches for patients with gastrointestinal (GI) cancers. Many GI tumors are detected late, which ultimately reduces 5-year overall survival rates. Liquid biopsies may become increasingly important both in the early detection and treatment...
Staying a Step Ahead of Cancer
When I was diagnosed with metastatic breast cancer in 2018, my first thought was, I hope my three young children do not lose two parents to cancer. My husband, Ricky, had survived two bouts of cancer, early-stage colorectal cancer and, most recently, stage I kidney cancer. Like Ricky’s two...
Project Orbis: Partnering With International Regulatory Agencies to Bring Earlier Global Access to Novel Cancer Treatments
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Preeti Narayan, MD, a medical oncologist and clinical reviewer on the Breast and Gynecologic Disease Team,...
Meta-analysis of Outcomes With Systemic Therapy in First- and Second-Line Treatments of Advanced HCC
In a systematic review and network meta-analysis reported in JAMA Oncology, Mohamad Bassam Sonbol, MD, of Mayo Clinic Cancer Center, Phoenix, and colleagues, found that atezolizumab plus bevacizumab outperformed other regimens in the first-line treatment of advanced hepatocellular carcinoma (HCC)...
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, London, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib alone in first-line treatment ...
Improved Outcomes With Neoadjuvant Paclitaxel Plus Trastuzumab/Lapatinib vs Paclitaxel/Trastuzumab in HER2-Positive Breast Cancer
In a 7-year follow-up of the phase III CALGB 40601/Alliance trial reported in the Journal of Clinical Oncology, Aranzazu Fernandez-Martinez, MD, of Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, and colleagues found that neoadjuvant paclitaxel combined with a dual...
No Reduced Recurrence Risk With Perioperative Aromatase Inhibitor Use in HR-Positive Breast Cancer
In the UK phase III POETIC trial reported in The Lancet Oncology, Ian Smith, MD, of The Royal Marsden NHS Foundation Trust, London, and colleagues, found that perioperative aromatase inhibitor therapy did not reduce the risk of recurrence in postmenopausal women with hormone receptor (HR)-positive...
ASCO Releases Guideline on Systemic Therapy for Advanced Hepatocellular Carcinoma
ASCO has released a new evidence-based clinical practice guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma.1 “Advanced hepatocellular carcinoma has transitioned from a disease where we had a single approved therapy for patients to one where we now...
What Is the Measure of Minimal Residual Disease in AML?
Relapse is the primary obstacle to cure in leukemia. The term minimal residual disease (MRD) was coined in the early 1990s to describe finding a disease-specific marker in the context of a morphologic-appearing remission. The technique first used for MRD detection was the Southern blot (!), but the ...
Facing Life’s Adversities, Even Cancer, From the Back of a Horse Named Buddy
“A bald eagle skims along the bluff where windblown Douglas firs, their exposed roots like talons, grip the eroding cliffs. Gulls circle and warn the bird of prey not to get too close. One hundred fifty feet below, the Salish Sea crashes and stretches west to the Pacific.” So begins Wild Ride Home: ...
The Lung Microbiome May Affect Lung Cancer Pathogenesis and Prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.1 “The...
Progress Report on Checkpoint Inhibitors in Rare Tumors
Immune checkpoint inhibitors may prove to be effective in treating patients with two rare cancer types—leptomeningeal metastases and angiosarcoma, according to early-phase clinical trials reported at the 2020 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which was held virtually ...
Immunotherapy for Triple-Negative Breast Cancer: An Evolving Story
Immunotherapy with checkpoint inhibitors, established as a treatment of many solid tumors, may be finding a role in the treatment of breast cancer. The current state of the art regarding immunotherapy for triple-negative breast cancer was the focus of a talk by Heather L. McArthur, MD, MPH, Medical ...
Emerging Data on PARP Inhibition in Prostate Cancer
Prostate cancer has lagged behind other solid tumors with regard to molecularly targeted therapy and precision medicine, with no targeted therapies approved specifically in prostate cancer, but that has changed with the recent approval in 2020 of a PARP (poly [ADP-ribose] polymerase) inhibitor for...
Understanding Breast Cancer Diagnosis and Treatment Disparities in Resource-Challenged Nations
Cancer is the second leading cause of death in the Caribbean. Adding to this growing burden, many of the nations in this geographically spread region have under-resourced health-care systems and a lack of cohesive approaches to the delivery of cancer care. To shed light on the public health...
Researchers Join $10 Million Project to Better Understand Sex Differences in Brain Cancer Outcomes
Researchers from Penn State College of Medicine are participating in a $10 million project to better understand why men and women with a common and deadly type of brain cancer have different survival rates. The investigators hope the study results can be used to develop new therapeutic approaches...
Physician-Scientist Judah Folkman, MD, Faced Years of Skepticism Before His Theory of Angiogenesis Was Proven
That Moses Judah Folkman would buck tradition, breaking his family’s long line of rabbinical succession and pursuing a career in science and medicine instead, was evident from the time he was a young child. Born in Cleveland on February 24, 1933, the first child of Rabbi Jerome and Bessie Folkman, ...
Expert Point of View: Joel W. Neal, MD, PhD
Invited discussant of the abstract, Joel W. Neal, MD, PhD, Associate Professor of Medicine at Stanford University, called this real-world analysis novel,1 given the decreasing number of patients treated with single-agent immunotherapy. “I think we’re unlikely to have a larger prospective study [in...
Lung Cancer Progression-Free Survival With Immunotherapy Varies Significantly by Tumor-Mutation Subtype, Real-World Data Show
A real-world study of single-agent immune checkpoint inhibitors in driver-mutated non–small cell lung cancer (NSCLC) has demonstrated significant variation in progression-free survival between mutation subtypes, according to data presented during the International Association for the Study of Lung...
Early-Stage Lung Cancer: An Overview of the Clinical Trial Landscape
Although early-stage, resectable disease represents the best chance for meaningful long-term survival and cure for patients with lung cancer, there are still high rates of recurrence. According to Rajwanth Veluswamy, MD, MSCR, neoadjuvant and adjuvant treatments are needed to improve surgical...
Low-Dose Radiotherapy for COVID-19–Related Pneumonia
Whole-lung low-dose radiation therapy led to quicker recovery from COVID-19–related pneumonia in hospitalized and oxygen-dependent patients compared with matched controls treated with best supportive care and physician’s choice of anti–COVID-19 therapy, according to the results of a small trial.1...
Single-Fraction SBRT May Be Equivalent to Four in Patients With Oligometastatic Lung Disease
Delivering stereotactic body radiation therapy (SBRT also called stereotactic ablative radiotherapy) in one or four treatment sessions led to similar outcomes in patients with up to three lung metastases (ie, oligometastatic disease) in the phase II randomized SAFRON II trial. The study, conducted...
Geriatric Assessment: Vital Element in Individualizing Care for Older Patients With Cancer
Caring for older adults with cancer is the purview of every oncologist. Over the next 30 years, the older adult population (65 years and older) will represent the fastest-growing segment of the world population. Globally, the number of persons 80 years and older is expected to triple from 143...
Living Well Before We Die
Editor’s Note: The following essay was first published in 2011. It is being reprinted here with permission from the author and publisher. In 2020, the American Academy of Hospice and Palliative Medicine (AAHPM) now includes more than 5,000 members; the annual meeting convenes more than 3,200...
Discerning the Underlying Mechanisms of Endometrial Cancer Disparities in Black Women
Endometrial cancer is the fourth most common cancer diagnosed in the United States, and the seventh most common cause of cancer death among women.1 This year, nearly 66,000 women will be diagnosed with the cancer, and about 12,600 will die of the disease.2 And although endometrial cancer is one of...
An Early Love of the Duck-Billed Platypus Sparks a Career in Cancer Research
Elaine R. Mardis, PhD, Co-Director of the Institute for Genomic Medicine at Nationwide Children’s Hospital, was born and reared in North Platte, a small city located in the west-central part of Nebraska. “My love of science was sparked and nurtured by my father, who was a chemistry professor for...
SABCS 2020: Patients With Breast Cancer Undergoing Radiotherapy May Have Underrecognized Side Effects
Among patients with breast cancer treated with radiotherapy, symptoms were commonly underrecognized in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom underrecognition. These findings were reported by Reshma...
Breaking the Cultural Norms: A Young Indian Girl Attains Her Dream of Becoming a Global Oncologist
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Bhawna Sirohi, FRCP, who is currently the lead medical oncologist at the Apollo Proton Cancer Centre in Chennai, Tamil Nadu, India. Along with her work in the clinic and her research endeavors, Dr....
SABCS 2020: Opioid and Sedative-Hypnotic Use After Mastectomy With Reconstructive Surgery
Women who undergo mastectomy with reconstructive surgery as part of breast cancer treatment may face the risk of persistent use of opioids and sedative-hypnotic drugs, according to data presented by Jacob Cogan, MD, and colleagues at the 2020 San Antonio Breast Cancer Symposium (Abstract GS3-08)....
SABCS 2020: Meta-analysis of Pregnancy Outcomes in Breast Cancer Survivors
A large meta-analysis of breast cancer survivors of childbearing age indicated that they are less likely than the general public to become pregnant and may face a higher risk of certain complications, such as preterm labor. However, most survivors who do become pregnant deliver healthy babies and...
SABCS 2020: Radiotherapy Omission After Breast-Conserving Surgery for Older Patients With HR-Positive Breast Cancer
Patients aged 65 or older with hormone receptor (HR)-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according ...
Interference of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-Free DNA Testing
In a study reported in JAMA Oncology, Jensen and colleagues found that clonal hematopoiesis of indeterminate potential (CHIP) involving DNA repair genes can interfere with prostate cancer plasma cell-free DNA testing used to determine eligibility for poly (ADP-ribose) polymerase (PARP) inhibitor...
Assessing the Progress Made in Global Cancer Care and Looking Toward the Future
In October 2020, Her Royal Highness Princess Dina Mired of Jordan ended her 2-year tenure as President of the Union for International Cancer Control (UICC), a global organization with more than 1,198 members from 172 countries and territories committed to reducing the cancer burden and...
ASCO Issues Comprehensive Recommendations to Strengthen Cancer Care and Research During and Beyond the COVID-19 Pandemic
On December 8, ASCO issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care...
